03282017Headline:

Archives

Home

Chad Finley

Deregulation and Budget Cuts Likely to Lead to Increased Adverse Event Reporting in Pharmaceutical Industry

With deregulation of FDA oversight, cuts in funding to institutions conducting government research and overview, and the potential for essentially the privatization of the FDA because of increased industry funding, it is likely we will see an increase in injuries and thus adverse event reports

Kendra Goldhirsch

Xarelto Manufacturers Eye New Patient Population as Lawsuits Continue

The anticoagulant drug Xarelto (rivaroxaban) is currently the subject of over 15,000 personal injury lawsuits pending in the Eastern District of Louisiana in a consolidated MDL litigation. Plaintiffs in these suits allege that after taking the drug, they suffered excessive […]

Shezad Malik MD JD

FDA Announces Heart Failure Warning for New Diabetic Medications

FDA announces Heart Failure Warning for new diabetic medications, Onglyza and Nesina. Type 2 diabetic patients are at increased risk of heart related complications from their disease and also suffer from life threatening side effects from the newer diabetic medications. […]

Chad Finley

Should I Report A Drug Injury or Drug Side Effect?

For all of these reasons, it is imperative that consumers understand that the need to report drug injuries or side effects is great. Reports are a critical way the FDA can detect injuries or side effects early and prevent it from unnecessarily happening to others

James Humann

Court Schedules Settlement Conferences for Cook IVC Litigation

The Cook Medical, Inc. IVC Filters Marketing, Sales Practices and Product Liability Litigation (MDL 2570) was established in the U.S. District Court for the Southern District of Indiana by the Judicial Panel of Multidistrict Litigation on October 15, 2014. Presently, […]

Roopal Luhana

FDA Drafts Guidelines on Off-Label Prescription Drug Marketing

Plaintiffs who file personal injury lawsuits against prescription drug manufacturers typically assert failure to warn claims, which provide that the drug makers failed to provide adequate warnings about the risks associated with their products. Instead, they argue that the manufacturers […]

Andrew D'Arcy

RISPERDAL  LAWSUITS

According to Johnson & Johnson’s most recent annual report, there are now 18,500 Risperdal lawsuits pending against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals in the US and Canada. Risperdal (risperidone) is an  antipsychotic approved by the Food and […]

Kendra Goldhirsch

JPML Consolidates Eliquis Litigation in New York

In October 2016, Eliquis manufacturers Bristol-Meyers Squibb and Pfizer Inc. submitted a petition to the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all Eliquis lawsuits into one court for pre-trial proceedings. They argued at the time that coordination […]

Edwin Booth

New Study Says Doctors Over-Prescribing Dangerous Drugs to Seniors

A new study recently published in JAMA (Journal of the American Medical Association) warns of the dangers associated with the increase in the amount of psychiatric medication that doctors are prescribing to seniors. The study found that the spike in […]

Roopal Luhana

Judge Fallon Sets New Dates for Xarelto Bellwether Trials

According to a recent Case Management Order entered in the Xarelto Multidistrict Litigation in federal court (Xarelto MDL), the first Xarelto bellwether trials have been delayed. The U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally filed Xarelto lawsuits […]